<DOC>
	<DOCNO>NCT02243787</DOCNO>
	<brief_summary>This study randomise , double-blind , placebo-controlled , sequential , ascend single-dose , parallel group study evaluate safety , tolerability , biological activity , systemic exposure COVA322 ( tumor necrosis factor alpha ( TNF-α ) / interleukin 17 A ( IL-17A ) antibody fusion protein ) patient stable chronic moderate-to-severe plaque psoriasis . Patients receive ascend single-doses COVA322 placebo constant-rate i.v . infusion , follow 12 week evaluation .</brief_summary>
	<brief_title>Safety Tolerability Study COVA322 Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female subject ethnic origin ; woman must nonchildbearing potential Aged 18 65 yr inclusive Body weight ≥ 40 kg body mass index 19 32 kg/m2 inclusive Established diagnosis moderate severe plaque psoriasis least 6 month prior screen . The patient must meet following criterion : Psoriasis involve ≥ 10 % body surface area Requirement phototherapy systemic therapy Psoriasis Area Severity Index ( PASI ) score ≥ 10 Physician‟s Global Assessment ( PGA ) score ≥ 3 stable disease History clinically relevant allergy idiosyncrasy COVA322 Any history clinically significant drug hypersensitivity follow therapy therapeutical biologic , asthma , urticaria , allergic diathesis Clinically significant flare psoriasis 12 week randomization Current evidence nonplaque form psoriasis Currently evidence druginduced psoriasis Evidence serious systemic local infection within 3 month screen Evidence subclinical/latent tuberculosis infection History sign lymphoproliferative disease , know malignancy history malignancy within previous 5 year History current evidence autoimmune disease psoriasis Women childbearing potential Recent previous exposure systemic psoriasis treatment , include antiTNFα therapy , immunosuppressive agent cyclosporine , mycophenolate , tacrolimus , medication affect immune function Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥ 2.5 time upper limit normal ( ULN ) screen Serum creatinine level ≥ 1.5 time ULN screen Positive result virology test HIVAb , hepatitis Cvirus antibody ( HCVAb ) hepatitis Bvirus surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>